You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
天壇生物(600161.SH)漲停 靜注COVID-19人免疫球蛋白獲批臨牀試驗
格隆匯 09-06 09:33
格隆匯9月6日丨天壇生物(600161.SH)開盤漲停報34.22元,市值470億元。近日,天壇生物公吿,旗下國藥集團武漢血液製品有限公司獲國家藥品監督管理局簽發的《藥物臨牀試驗批件》,將開展“靜注 COVID-19 人免疫球蛋白(pH4)”臨牀試驗。靜注COVID-19人免疫球蛋白(pH4)為治療用生物製品一類新藥,是全球首款採用新冠滅活疫苗免疫後血漿製備的新冠肺炎特異性治療藥物,也是國藥集團中國生物抗擊新冠科研攻關團隊在治療領域的又一突破性成果。公吿顯示,該產品原料來自於經疫苗免疫的健康人血漿,並經抗體效價篩選。由於當前國內疫情緩解,武漢血制計劃在海外開展相關臨牀試驗。靜注COVID-19人免疫球蛋白是第八版新型冠狀病毒肺炎診療方案納入的三種免疫療法之一。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account